Abstract
Highly sensitive troponin (hsTn) assays may predict cardiovascular (CV) events and left ventricular (LV) remodeling in patients with heart failure (HF). In this study, 99 subjects with LV systolic dysfunction (LVSD) were followed 10 ± 3 months with serial measurement of hsTnI by a novel method. hsTnI was detectable in all subjects and was above the 99th percentile of a normal population in 56.7 %. Supramedian baseline hsTnI concentration was associated with higher-risk clinical features and shorter time-to-first event (p = 0.008). Across serial measurements, more time spent ≤10.9 pg/mL was associated with a lower CV event rate after adjustment (odds ratio (OR) = 0.81; p = 0.008); rising hsTnI also predicted progressive LV remodeling. In conclusion, hsTnI detected significant myocardial necrosis in a majority of patients with chronic HF due to LVSD and when measured serially, provided independent risk information for poor CV outcomes and deleterious LV remodeling.
This is a preview of subscription content, access via your institution.



Similar content being viewed by others
Abbreviations
- hsTnI:
-
Highly sensitive troponin I
- CV:
-
Cardiovascular
- HF:
-
Heart failure
- LV:
-
Left ventricular
- LVSD:
-
Left ventricular systolic dysfunction
- PROTECT:
-
Pro-BNP Outpatient Tailored Chronic Heart Failure Therapy
- NT-proBNP:
-
Amino-terminal pro-B type natriuretic peptide
- TTE:
-
Transthoracic echocardiogram
- LVEF:
-
Left ventricular ejection fraction
- LVESVi:
-
Left ventricular end systolic volume index
- LVEDVi:
-
Left ventricular end diastolic volume index
- SD:
-
Standard deviation
- IQR:
-
Interquartile range
- NYHA:
-
New York Heart Association
- eGFR:
-
Estimated glomerular filtration rate
References
Thygesen, K., Alpert, J. S., Jaffe, A. S., Simoons, M. L., Chaitman, B. R., White, H. D., Joint ESCAAHAWHFTFftUDoMI, Katus, H. A., Lindahl, B., Morrow, D. A., Clemmensen, P. M., Johanson, P., Hod, H., Underwood, R., Bax, J. J., Bonow, R. O., Pinto, F., Gibbons, R. J., Fox, K. A., Atar, D., Newby, L. K., Galvani, M., Hamm, C. W., Uretsky, B. F., Steg, P. G., Wijns, W., Bassand, J. P., Menasche, P., Ravkilde, J., Ohman, E. M., Antman, E. M., Wallentin, L. C., Armstrong, P. W., Simoons, M. L., Januzzi, J. L., Nieminen, M. S., Gheorghiade, M., Filippatos, G., Luepker, R. V., Fortmann, S. P., Rosamond, W. D., Levy, D., Wood, D., Smith, S. C., Hu, D., Lopez-Sendon, J. L., Robertson, R. M., Weaver, D., Tendera, M., Bove, A. A., Parkhomenko, A. N., Vasilieva, E. J., & Mendis, S. (2012). Third universal definition of myocardial infarction. Circulation, 126(16), 2020–2035. doi:10.1161/CIR.0b013e31826e1058.
Januzzi, J. L., Jr., Filippatos, G., Nieminen, M., & Gheorghiade, M. (2012). Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section. European Heart Journal, 33(18), 2265–2271. doi:10.1093/eurheartj/ehs191.
Horwich, T. B., Patel, J., MacLellan, W. R., & Fonarow, G. C. (2003). Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation, 108(7), 833–838. doi:10.1161/01.CIR.0000084543.79097.34.
Wang, T. J., Wollert, K. C., Larson, M. G., Coglianese, E., McCabe, E. L., Cheng, S., Ho, J. E., Fradley, M. G., Ghorbani, A., Xanthakis, V., Kempf, T., Benjamin, E. J., Levy, D., Vasan, R. S., & Januzzi, J. L. (2012). Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation, 126(13), 1596–1604. doi:10.1161/CIRCULATIONAHA.112.129437.
de Lemos, J. A., Drazner, M. H., Omland, T., Ayers, C. R., Khera, A., Rohatgi, A., Hashim, I., Berry, J. D., Das, S. R., Morrow, D. A., & McGuire, D. K. (2010). Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA, 304(22), 2503–2512. doi:10.1001/jama.2010.1768.
Egstrup, M., Schou, M., Tuxen, C. D., Kistorp, C. N., Hildebrandt, P. R., Gustafsson, F., Faber, J., Goetze, J. P., & Gustafsson, I. (2012). Prediction of outcome by highly sensitive troponin T in outpatients with chronic systolic left ventricular heart failure. The American Journal of Cardiology, 110(4), 552–557. doi:10.1016/j.amjcard.2012.04.033.
Masson, S., Anand, I., Favero, C., Barlera, S., Vago, T., Bertocchi, F., Maggioni, A. P., Tavazzi, L., Tognoni, G., Cohn, J. N., Latini, R., & Valsartan Heart Failure T, Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure I. (2012). Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials. Circulation, 125(2), 280–288. doi:10.1161/CIRCULATIONAHA.111.044149.
Gaggin, H. K., Szymonifka, J., Bhardwaj, A., Belcher, A., De Berardinis, B., Motiwala, S., Wang, T. J., & Januzzi, J. L., Jr. (2014). Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure. JACC Heart Failure, 2(1), 65–72. doi:10.1016/j.jchf.2013.10.005.
Januzzi, J. L., Jr., Rehman, S., Mohammed, A. A., Bhardwaj, A., Barajas, L., Barajas, J., Kim, H.-N., Baggish, A. L., Weiner, R. B., Chen, A. A., Marshall, J. E., Moore, S. A., Carlson, W. D., Lewis, G. D., Shin, J., Sullivan, D., Parks, K., Wang, T. J., Gregory, S., Uthamalingam, S., & Semigran, M. J. (2011). Use of amino-terminal pro-B type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. Journal of the American College of Cardiology, 58, 1881–1889.
Bhardwaj, A., Rehman, S. U., Mohammed, A., Baggish, A. L., Moore, S. A., & Januzzi, J. L., Jr. (2010). Design and methods of the pro-B type natriuretic peptide outpatient tailored chronic heart failure therapy (PROTECT) Study. American Heart Journal, 159(4), 532–538. doi:10.1016/j.ahj.2010.01.005. e531.
Lang, R. M., Bierig, M., Devereux, R. B., Flachskampf, F. A., Foster, E., Pellikka, P. A., Picard, M. H., Roman, M. J., Seward, J., Shanewise, J. S., Solomon, S. D., Spencer, K. T., Sutton, M. S., & Stewart, W. J. (2005). Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. Journal of the American Society of Echocardiography: Official Publication of the American Society of Echocardiography, 18(12), 1440–1463. doi:10.1016/j.echo.2005.10.005.
Gaggin, H. K., Truong, Q. A., Rehman, S. U., Mohammed, A. A., Bhardwaj, A., Parks, K. A., Sullivan, D. A., Chen-Tournoux, A., Moore, S. A., Richards, A. M., Troughton, R. W., Lainchbury, J. G., Weiner, R. B., Baggish, A. L., Semigran, M. J., & Januzzi, J. L., Jr. (2013). Characterization and prediction of natriuretic peptide "nonresponse" during heart failure management: results from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) and the NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissions and Death (BATTLESCARRED) study. Congestive Heart Failure, 19(3), 135–142. doi:10.1111/chf.12016.
Motiwala, S. R., Szymonifka, J., Belcher, A., Weiner, R. B., Baggish, A. L., Sluss, P., Gaggin, H. K., Bhardwaj, A., & Januzzi, J. L. (2013). Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. European Journal of Heart Failure, 15(10), 1157–1163. doi:10.1093/eurjhf/hft075.
Miller, W. L., Hartman, K. A., Burritt, M. F., Grill, D. E., & Jaffe, A. S. (2009). Profiles of serial changes in cardiac troponin T concentrations and outcome in ambulatory patients with chronic heart failure. Journal of the American College of Cardiology, 54(18), 1715–1721. doi:10.1016/j.jacc.2009.07.025.
Sources of Funding
This work was supported in part by Singulex, which had no role in data analysis or initial manuscript preparation. Dr. Motiwala was supported by the Dennis and Marilyn Barry Fellowship in Cardiology, Dr. Gaggin is supported in part by the Clark Fund for Cardiac Research Innovation, and Dr. Januzzi is supported in part by the Roman W. DeSanctis Clinical Scholar Endowment.
Disclosures
Dr. Januzzi has received grant support from Roche Diagnostics, Singulex, Critical Diagnostics, Siemens, and BRAHMS and consulting revenue from Novartis, Zensun, Amgen, Radiometer, and Boeringer Ingelheim. All other authors have no conflicts of interest to declare.
Human Subjects/Informed Consent
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained from all patients for being included in the study.
Animal Studies
No animal studies were carried out by the authors for this article.
Author information
Authors and Affiliations
Corresponding author
Additional information
Associate Editor Daniel P. Judge oversaw the review of this article
Rights and permissions
About this article
Cite this article
Motiwala, S.R., Gaggin, H.K., Gandhi, P.U. et al. Concentrations of Highly Sensitive Cardiac Troponin-I Predict Poor Cardiovascular Outcomes and Adverse Remodeling in Chronic Heart Failure. J. of Cardiovasc. Trans. Res. 8, 164–172 (2015). https://doi.org/10.1007/s12265-015-9618-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12265-015-9618-4